Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514127 | 0.89 | PRKD3 (0.43) | AAK1PRKD3PRKD1PRKD2SYK | |
| SCHEMBL3979090 | 0.86 | PRKD3 (0.41) | AAK1PRKD3PRKD1PRKD2SYK | |
| SCHEMBL3979083 | 0.86 | PRKD3 (0.41) | AAK1PRKD3PRKD1PRKD2SYK | |
| SCHEMBL4509993 | 0.80 | EGFR (0.43) | AAK1SYKALDH1A1MAPTEGFR | |
| SCHEMBL3912256 | 0.78 | PRKD3 (0.64) | PRKD3PRKD1PRKD2ALDH1A1MAPT | |
| SCHEMBL3912253 | 0.78 | PRKD3 (0.64) | PRKD3PRKD1PRKD2ALDH1A1MAPT | |
| SCHEMBL3912247 | 0.78 | PRKD3 (0.64) | PRKD3PRKD1PRKD2ALDH1A1MAPT | |
| SCHEMBL3978239 | 0.77 | SYK (0.38) | AAK1PRKD3PRKD1PRKD2SYK | |
| SCHEMBL3978233 | 0.77 | SYK (0.38) | AAK1PRKD3PRKD1PRKD2SYK | |
| SCHEMBL3910866 | 0.76 | SYK (0.39) | AAK1SYKALDH1A1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-2024333-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | AAK1 46/4885PRKD3 9/4885PRKD1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.